BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V:
Post# of 69
(Total Views: 225)
Posted On: 12/28/2018 6:39:11 PM
BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Advancing Its Clinical Program, Immunotherapy Seen as Future of Cancer Treatment
- Multiple oncology and immunology organizations have identified immunotherapy as the future of cancer treatment
- BriaCell Therapeutics Corp. is making significant progress in the development of a safe and highly effective immunotherapy solution for advanced breast cancer patients
- The company is expected to announce new information about the efficacy of its lead product candidate in combination with KEYTRUDA® during the first quarter of 2019
- Market forecasts suggest rapid anti-cancer immunotherapy market growth until 2023
For nearly 20 years, researchers have been working on ways to help the immune system better target cancer. New developments in the field are making that possible, which is why clinicians believe that immunotherapy could be the future of cancer treatment (http://nnw.fm/dMO66). According to the British Society of Immunology, the rise of monoclonal antibodies that can be raised against a protein of interest is changing the landscape of cancer treatments. Several such antibodies have already become available, and they can be used to target different types of cancer.
Companies like BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a Berkeley-based clinical-stage biotechnology company focused on the development of targeted immunotherapy for advanced breast cancer, are making solid progress in the field of immunotherapy aimed at targeting specific types of cancer. Bria-IMT™, the company’s lead product candidate, has delivered promising results in three clinical studies to date. Bria-IMT™ has resulted in tumor shrinkage in certain patients with advanced stage breast cancer. It is now being evaluated in combination with KEYTRUDA® (pembrolizumab) from Merck & Co., Inc. (NYSE: MRK).
Bria-IMT™ works by providing breast cancer antigens and a direct stimulation of the cancer fighting T-cells. This way, the therapy strengthens the body’s ability to fight cancer. Bria-IMT™ has achieved proof of concept in clinical trials, and its safety has also been assessed as excellent. Even in heavily pre-treated advanced breast cancer patients, Bria-IMT™ managed to elicit tumor regression.
In the combination study, six patients have been treated with Bria-IMT™ and KEYTRUDA®. In all of the patients, the combination was very well tolerated, and the study is ongoing. Additional data about the efficacy of the combination study is expected in the first quarter of 2019, BriaCell announced.
Based on these findings, BriaCell Therapeutics Corp. is also working on Bria-OTS™ – a personalized, off-the-shelf immunotherapy solution for advanced breast cancer patients. Bria-OTS™ will provide a first-of-its-kind personalized immunotherapy that is much more cost-efficient and easier to manufacture than other comparable solutions. According to BriaCell, the technology could also be applicable to the treatment of other types of cancer.
The global cancer immunotherapy market is projected to grow rapidly in the coming years, at a CAGR of 12.9 percent through 2023 (http://nnw.fm/z7Xps). This means that, by 2022, the market volume is expected to exceed $145 billion (http://nnw.fm/hp7Ho). By 2026, nearly 60 percent of previously treated cancer patients will probably adopt immunotherapy (http://nnw.fm/IFT0w).
The rising incidence and prevalence of multiple types of cancer will also propel the development of effective immunotherapy solutions like BriaCell’s Bria-IMT™ and Bria-OTS™.
For more information, visit the company’s website at www.BriaCell.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Multiple oncology and immunology organizations have identified immunotherapy as the future of cancer treatment
- BriaCell Therapeutics Corp. is making significant progress in the development of a safe and highly effective immunotherapy solution for advanced breast cancer patients
- The company is expected to announce new information about the efficacy of its lead product candidate in combination with KEYTRUDA® during the first quarter of 2019
- Market forecasts suggest rapid anti-cancer immunotherapy market growth until 2023
For nearly 20 years, researchers have been working on ways to help the immune system better target cancer. New developments in the field are making that possible, which is why clinicians believe that immunotherapy could be the future of cancer treatment (http://nnw.fm/dMO66). According to the British Society of Immunology, the rise of monoclonal antibodies that can be raised against a protein of interest is changing the landscape of cancer treatments. Several such antibodies have already become available, and they can be used to target different types of cancer.
Companies like BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a Berkeley-based clinical-stage biotechnology company focused on the development of targeted immunotherapy for advanced breast cancer, are making solid progress in the field of immunotherapy aimed at targeting specific types of cancer. Bria-IMT™, the company’s lead product candidate, has delivered promising results in three clinical studies to date. Bria-IMT™ has resulted in tumor shrinkage in certain patients with advanced stage breast cancer. It is now being evaluated in combination with KEYTRUDA® (pembrolizumab) from Merck & Co., Inc. (NYSE: MRK).
Bria-IMT™ works by providing breast cancer antigens and a direct stimulation of the cancer fighting T-cells. This way, the therapy strengthens the body’s ability to fight cancer. Bria-IMT™ has achieved proof of concept in clinical trials, and its safety has also been assessed as excellent. Even in heavily pre-treated advanced breast cancer patients, Bria-IMT™ managed to elicit tumor regression.
In the combination study, six patients have been treated with Bria-IMT™ and KEYTRUDA®. In all of the patients, the combination was very well tolerated, and the study is ongoing. Additional data about the efficacy of the combination study is expected in the first quarter of 2019, BriaCell announced.
Based on these findings, BriaCell Therapeutics Corp. is also working on Bria-OTS™ – a personalized, off-the-shelf immunotherapy solution for advanced breast cancer patients. Bria-OTS™ will provide a first-of-its-kind personalized immunotherapy that is much more cost-efficient and easier to manufacture than other comparable solutions. According to BriaCell, the technology could also be applicable to the treatment of other types of cancer.
The global cancer immunotherapy market is projected to grow rapidly in the coming years, at a CAGR of 12.9 percent through 2023 (http://nnw.fm/z7Xps). This means that, by 2022, the market volume is expected to exceed $145 billion (http://nnw.fm/hp7Ho). By 2026, nearly 60 percent of previously treated cancer patients will probably adopt immunotherapy (http://nnw.fm/IFT0w).
The rising incidence and prevalence of multiple types of cancer will also propel the development of effective immunotherapy solutions like BriaCell’s Bria-IMT™ and Bria-OTS™.
For more information, visit the company’s website at www.BriaCell.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)